The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
2007

BRCA1/2 Pathway and Hematologic Cancers

Sample size: 363 publication Evidence: high

Author Information

Author(s): Friedenson Bernard

Primary Institution: Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois Chicago

Hypothesis

Inactivation of virtually any component within the pathway containing the BRCA1 and BRCA2 proteins would increase the risks for lymphomas and leukemias.

Conclusion

The BRCA pathway is essential to prevent a subgroup of human leukemias and lymphomas that may involve non-random, characteristic gene rearrangements.

Supporting Evidence

  • Deleterious mutations of genes in the BRCA pathway increased risks up to nearly 2000 fold for certain leukemias and lymphomas.
  • Mantle cell lymphoma is associated with a characteristic rearrangement of DNA fragments between chromosomes 11 and 14.
  • Meta-analysis showed strong odds ratios for an ATM-MCL association across multiple studies.

Takeaway

The BRCA1 and BRCA2 proteins help prevent certain blood cancers, and if they don't work properly, the risk of these cancers goes way up.

Methodology

Literature searches and meta-analyses of epidemiology and basic science articles related to the BRCA pathway were conducted.

Potential Biases

Potential bias due to the rarity of mutations in some molecules and reliance on existing literature.

Limitations

Access to original data is limited, and some studies may not provide required data for analysis.

Participant Demographics

The study included data from various epidemiological studies over the past 20 years.

Statistical Information

P-Value

p<0.0001

Confidence Interval

95% CI = 34.59–142.72

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1186/1471-2407-7-152

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication